Alnylam shares lag despite Q1 profit breakthrough as RNAi pioneer's valuation divides Wall Street
Alnylam Pharmaceuticals, the US biotech that has long been the standard-bearer for the RNA interference therapeutic class, has swung to a quarterly profit on the back of a surge in product sales, marking a watershed for a company whoseâŠ
